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Abstract
Objective: The objective of this study was to evaluate prespecified and post
hoc analyses in RENEW subgroups to identify participants more likely to ben-
efit from opicinumab. Methods: RENEW assessed the efficacy/safety of opici-
numab versus placebo in participants with a first unilateral acute optic
neuritis (AON) episode. Difference in visual evoked potential (VEP) latency of
the affected eye at 24 weeks versus the fellow eye at baseline was the primary
endpoint. Interactions between the primary endpoint and prespecified baseline
variables (including age, timing of treatment initiation, and visual impairment)
using the median as cut-off were evaluated in the per protocol population
using analysis of covariance (ANCOVA); subgroups based on preexisting brain
T2 lesion volume were also analyzed. Interactions between the primary end-
point and retinal ganglion cell layer/inner plexiform layer (RGCL/IPL) and
retinal nerve fiber layer (RNFL) thickness were assessed post hoc as was
weight gain by treatment. Results: Treatment benefit of opicinumab (n = 33)
over placebo (n = 36) on the primary endpoint was greatest in participants
older than the median age at baseline (≥33 years); the difference versus pla-
cebo for baseline age ≥33 years was 14.17 msec [P = 0.01] versus
0.89 msec for baseline age <33 years, [P = 0.87]). Post hoc analysis showed
that VEP latency recovery was significantly associated with less RGCL/IPL
thinning (P = 0.0164), occurring early on. Interpretation: Age was the stron-
gest prespecified baseline characteristic associated with a treatment effect of
opicinumab. A strong association between VEP latency recovery at week 24
and early RGCL/IPL preservation was observed.
Introduction
Acute optic neuritis (AON), frequently the first manifes-
tation of multiple sclerosis (MS), is characterized by optic
nerve inflammatory demyelination and axonal injury.
While some spontaneous remyelination occurs, most
patients have residual structural and clinical deficits.1–4 A
physiological hallmark of AON is prolonged visual evoked
potential (VEP) latency, resulting from persistent
demyelination of the affected optic nerve.2,5
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Therapies enhancing remyelination and thus supporting
axonal integrity and function remain an unmet need for
demyelinating diseases such as AON and MS.6 Opicinu-
mab (anti-LINGO-1, BIIB033) is a human monoclonal
antibody against leucine-rich repeat and immunoglobu-
lin-like domain-containing protein 1 (LINGO-1; an oligo-
dendrocyte differentiation and myelination suppressor)
that was genetically engineered to reduce immunoglobulin
effector function. In preclinical models, opicinumab has
no apparent effects on the immune system; remyelina-
tion/neuroprotection effects in the central nervous system
(CNS) as well as acceptable tolerability were observed.7–10
Therefore, opicinumab is being further tested in Phase II
proof-of-biology/concept studies.
In RENEW, previously healthy participants with a first
unilateral AON episode were randomized to opicinumab
or placebo intravenous (IV) infusions every 4 weeks. The
primary endpoint was the difference in full-field VEP
latency of the affected eye at 24 weeks versus baseline of
the unaffected fellow eye in the intent-to-treat (ITT) pop-
ulation. Efficacy for opicinumab versus placebo was also
examined at the end of study (week 32) in the ITT popu-
lation, and at 24 and 32 weeks in the per protocol (PP)
population. Although the ITT analysis did not demon-
strate a statistically significant treatment effect, the PP
analysis showed improvement in mean VEP latency favor-
ing the opicinumab-treated cohort, with treatment effect
most evident at week 32 versus week 24. The overall inci-
dence and severity of adverse events were comparable
between treatment groups, except for two treatment-
emergent adverse events, hypersensitivity reactions and
mild-moderate weight gain that were more frequent in
the opicinumab group.11
Designed as a proof-of-concept study, RENEW was not
powered for statistical significance; it aimed to investigate
baseline demographic and disease characteristics associ-
ated with treatment response to LINGO-1 blockade for
remyelination and neuroprotection with opicinumab.
Here we present results of the prespecified efficacy analy-
ses aimed to identify participant subgroups more likely to
benefit from opicinumab, as well as a post hoc analysis of
baseline characteristics associated with weight gain and
relationships between structural and functional endpoints.
Methods
Study design and participants
RENEW (NCT01721161) was a previously reported ran-
domized, double-masked, placebo-controlled, multicenter
study.11 Eligible participants were previously healthy
adults with no history of MS who were experiencing a
first unilateral AON episode, with normal VEP in the
fellow eye. All participants were treated with high-dose
methylprednisolone (1 g IV/day for 3–5 days), then ran-
domized 1:1 within 28 days of first symptom onset to
placebo or 100 mg/kg opicinumab IV every 4 weeks (total
of 6 infusions) and followed to end of treatment (week
24) and end of study (week 32).11
The primary outcome, difference in VEP latency for
the affected eye from the baseline of the unaffected fellow
eye, was recorded at weeks 24 and 32 using P100 latency
(msec).11 The average normal P100 latency is
~100 msec.12 Latency prolongation was also measured as
the interocular difference by comparing the affected eye
at all time points with the baseline value for the unaf-
fected fellow eye. The fellow eye was selected as the refer-
ence control because baseline latency in the affected eye is
not measurable in the acute setting due to conduction
block and residual inflammation post high-dose IV ster-
oids. Neuroaxonal retinal thinning, a secondary endpoint
assessing potential neuroprotective treatment effects of
opicinumab on retinal ganglion cells (RGC) and the reti-
nal nerve fiber layer (RNFL), was measured using the
Duke Optical Coherence Tomography Retinal Analysis
Program (DOCTRAP) software on two different spectral-
domain optical coherence tomography (SD-OCT) systems
– either the Cirrus HD-OCT (Carl Zeiss Meditec, Inc.,
Dublin, California) or Spectralis (Heidelberg Engineering,
Inc., Franklin, Massachusetts) devices.13,14 Assessments
were performed according to prespecified standard proto-
cols and interpreted by a central reader with strict quality
control.11 Due to reading differences between the Cirrus
and Spectralis devices and analysis software, RNFL thin-
ning was reported as a percentage. On the other hand, a
value in microns could be used for retinal ganglion cell
layer/inner plexiform layer (RGCL/IPL) thinning, because
using fellow eye baseline measurements in this study,
DOCTRAP results were generally comparable between
Cirrus and Spectralis scans (unpublished). VEP ampli-
tude, high-contrast visual acuity (HCVA), and low-con-
trast letter acuity (LCLA; 1.25% and 2.5% Sloan charts)
also were assessed.11
Participants who completed the study, missed ≤1 dose,
and did not receive MS disease-modifying therapy were
included in the prespecified PP population. The safety
and ITT populations comprised all participants who
received ≥1 study dose.11 For the subgroup analyses
reported in this manuscript, we focused on the PP popu-
lation but also reported findings in the ITT population as
supplementary material.
Subgroup analyses for the PP population
A subgroup analysis for the PP population was performed
because this cohort most closely adhered to the treatment
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protocol, was free of imputations, and had stronger treat-
ment effects than the ITT study population. The primary
efficacy endpoint was assessed in prespecified subgroups
of participants classified by the following baseline demo-
graphic and disease characteristics: age, days between
onset of AON and initiation of study treatment, days
between completing steroid therapy and study treatment
initiation, LCLA score in affected eye, HCVA score in
affected eye, and brain T2 lesion volume. With the excep-
tion of brain T2 lesion volume, the median value was
used as the cutoff to classify the subgroups for each of
the baseline characteristics; 0 and >0 were used for base-
line brain T2 lesion volume.
VEP latency recovery (to normal) was prespecified as
affected eye VEP latency ≤10% worse than the baseline
fellow eye.11 Post hoc analyses were performed to deter-
mine the interaction between VEP latency recovery (over
24 weeks) and RGCL/IPL thickness, irrespective of treat-
ment group. We also compared participants with and
without VEP latency recovery for corresponding changes
over 24 weeks in VEP amplitude, RNFL thickness, LCLA
score, and HCVA score.
Subgroup analyses for the safety
population
The prespecified safety analyses showed that the overall
incidence and severity of adverse events in RENEW were
comparable between the opicinumab and placebo groups.
However, weight gain during the study was found to be
greater in opicinumab- than placebo-treated partici-
pants.11 Hence, post hoc analyses of participants who had
weight gain >7% during the study were undertaken to
determine whether any baseline characteristics were asso-
ciated with this outcome. A 7% change in weight from
baseline is a frequently used cutoff to assess weight gain
or loss in clinical studies.
Statistical analyses
For participants classified by prespecified baseline charac-
teristics, the adjusted mean change for each treatment
group at week 24, difference compared with placebo, 95%
confidence interval (CI), and P-value (compared with pla-
cebo and subgroup-by-treatment interaction) were evalu-
ated by analysis of covariance (ANCOVA). The adjusted
mean change in efficacy endpoints also was determined
for the groups of participants with and without latency
recovery at week 24, and the difference between these
groups (with 95% CI and P-value) was calculated using
ANCOVA. Post hoc sensitivity analyses were performed
to determine if 10% was an appropriate cut-off to define
latency recovery.11 Means and standard deviations for
baseline characteristics in participants with and without
post-baseline weight increase >7% were calculated.
Results
Randomized participants
Eighty-two participants were randomized to placebo or
opicinumab. The baseline clinical and demographic char-
acteristics were similar in both groups of the ITT and PP
populations, with the exception of more AON severe cases
randomized to opicinumab than placebo.11 Baseline VEP
latency in the affected eye was not measurable in a num-
ber of participants in the acute setting due to conduction
failure (affected eye conduction failure at baseline: ITT,
n = 15; PP, n = 11). Sixty-nine participants comprised the
PP population, 36 randomized to placebo and 33 to opici-
numab; 82 participants were included in the ITT and
safety population, 41 in each treatment group.11
Efficacy subgroup analyses in the PP
population
The primary endpoint analysis in subgroups classified by
prespecified baseline characteristics showed that the treat-
ment benefit for opicinumab versus placebo at week 24
was largest in the older subgroup of participants
(≥33 years of age; 14.17 msec (24.83, 3.52) versus
the younger subgroup (<33 years of age; 0.89 msec
[11.43, 9.65]), reaching statistical significance
(P = 0.01); there was only a trend in the subgroup-by-
treatment interaction. Moreover, trends for increased ben-
efit were observed in participants who received the first
dose sooner (<25 days from the onset of AON) and in
participants with more severe pretreatment visual acuity
impairment (HCVA score <49; Tables 1 and 2; see
Table S1 for results in the ITT population). Although
none of the other subgroups based on baseline character-
istics reached statistical significance on the primary end-
point, there was a consistent treatment difference favoring
opicinumab across all prespecified treatment subgroups
examined (Tables 1 and 2).
For interactions between functional (VEP) and struc-
tural (SD-OCT) outcomes in the visual pathway analyzed
post hoc, significantly less RGCL/IPL thinning was
observed in the subgroup of participants with VEP
latency recovery than in participants without latency
recovery (Fig. 1, left panel). After 24 weeks, there was
minimal, if any, additional RGCL/IPL thinning (Fig. 1,
right panel). Similar results were observed in the ITT
population (Fig. S1).
Additional analyses of differences at week 24 between
participants classified according to VEP latency recovery
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showed that absence of VEP latency recovery corre-
sponded to worse average outcomes on VEP amplitude,
1.25% LCLA, and 2.5% LCLA than those with latency
recovery (Table 3). None of these observations reached
statistical significance (see Table S2 for data in the ITT
population).
Safety subgroup analyses
Seventeen participants in the RENEW study had weight
gain >7% from baseline, 4 (10%) in the placebo group
and 13 (32%) in the opicinumab group.11 Post hoc sub-
group analyses showed that participants in the
Table 1. Differences in VEP latencies at week 24 in the affected eye compared with the unaffected fellow eye and treatment difference for
opicinumab versus placebo for PP population subgroups classified by prespecified demographic and time to treatment baseline characteristics.
Adjusted mean change in VEP at week 24 by baseline characteristic Placebo Opicinumab
Treatment difference
(95% CI); P-value
Age
<33 years 17.83 (n = 17) 16.93 (n = 17) 0.89 (11.43, 9.65)
P = 0.87
≥33 years 26.32 (n = 19) 12.15 (n = 16) 14.17 (24.83, 3.52)
P = 0.01
Subgroup-by-treatment interaction P-value P = 0.08
Treatment window
Received treatment <25 days from onset of AON 20.20 (n = 16) 11.19 (n = 14) 9.01 (20.44, 2.42)
P = 0.12
Received treatment ≥25 days from onset of AON 23.91 (n = 20) 17.23 (n = 19) 6.68 (16.75, 3.39)
P = 0.19
Subgroup-by-treatment interaction P-value P = 0.76
Timing of steroid administration
Received treatment <15 days after completing steroid therapy 22.01 (n = 20) 13.80 (n = 14) 8.21 (19.20, 2.78)
P = 0.14
Received treatment ≥15 days after completing steroid therapy 22.52 (n = 16) 15.36 (n = 19) 7.16 (18.09, 3.77)
P = 0.20
Subgroup-by-treatment interaction P-value P = 0.89
AON, acute optic neuritis; CI, confidence interval; PP, per-protocol; VEP, visual evoked potential.
Table 2. Difference in VEP latencies at week 24 in the affected eye compared to the baseline of the unaffected fellow eye and treatment differ-
ence for opicinumab versus placebo for PP population subgroups classified by prespecified disease baseline characteristics.
Adjusted mean change in VEP at week 24 by baseline characteristic Placebo Opicinumab
Treatment difference
(95% CI); P-value
LCLA impairment
LCLA score = 0 (2.5% chart) 25.68 (n = 21) 19.22 (n = 11) 6.46 (18.01, 5.10)
P = 0.27
LCLA score >0 (2.5% chart) 17.40 (n = 15) 13.61 (n = 20) 3.79 (14.40, 6.82)
P = 0.48
Subgroup-by-treatment interaction P-value P = 0.73
HCVA impairment
HCVA score <49 25.21 (n = 16) 14.29 (n = 12) 10.92 (23.01, 1.18)
P = 0.08
HCVA score ≥49 19.80 (n = 20) 15.66 (n = 20) 4.14 (14.14, 5.86)
P = 0.41
Subgroup-by-treatment interaction P-value P = 0.39
MRI burden of disease
Brain T2 lesion volume = 0 17.88 (n = 5) 7.40 (n = 8) 10.48 (28.35, 7.38)
P = 0.25
Brain T2 lesion volume >0 22.21 (n = 29) 17.08 (n = 25) 5.13 (13.66, 3.40)
P = 0.23
Subgroup-by-treatment interaction P-value P = 0.59
CI, confidence interval; HCVA, high-contrast visual acuity; LCLA, low-contrast letter acuity; MRI, magnetic resonance imaging; PP, per-protocol;
VEP, visual evoked potential.
ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 1157
D. Cadavid et al. Treatment Response to Opicinumab in AON
opicinumab arm with weight gain >7% during the study
had worse baseline AON disease, indicated by worse
HCVA impairment, greater VEP latency prolongation,
and a higher frequency of conduction failure (absence of
VEP P100 amplitude wave) at baseline. However, this was
not consistent for the placebo group because VEP latency
delay and worse HCVA impairment were more common
among patients without weight gain >7%.
Discussion
The RENEW study was the first to investigate, in
humans, the potential efficacy of LINGO-1 blockade
with opicinumab for enhancing remyelination using the
difference in VEP latency of the affected eye at 24 weeks
versus the fellow eye at baseline as the primary outcome
measure. VEP latency is a sensitive indicator of
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Figure 1. Retinal ganglion cell layer/inner plexiform layer (RGCL/IPL) thinning (spectral-domain optical coherence tomography) at weeks 4 and 24
in participants from the per-protocol population with and without visual evoked potential (VEP) latency recovery. CI, confidence interval.
Table 3. Post hoc analyses of efficacy endpoints in participants from the PP population without versus with VEP latency recovery at week 24.
Endpoint
Without VEP latency
recovery at week 24
n = 38
With VEP latency
recovery at week 24
n = 28
Difference versus
without latency
recovery (95% CI);
P-value
Adjusted mean change in VEP amplitude, lV1 3.43 2.57 0.85 (1.28, 2.99)
P = 0.43
Adjusted mean change in RGCL/IPL thickness (SD-OCT), lm1 12.67 8.15 4.52 (0.86, 8.17)
P = 0.02
Adjusted mean percentage change in RNFL thickness (SD-OCT)1 16.22 10.73 5.49 (0.72, 11.70)
P = 0.08
Adjusted mean change in LCLA,1.25% Sloan chart2 5.64 8.87 3.23 (2.52, 8.97)
P = 0.27
Adjusted mean change in LCLA, 2.5% Sloan chart2 11.08 12.69 1.61 (4.56, 7.78)
P = 0.60
Adjusted mean change in HCVA2 11.16 9.74 1.42 (6.47, 3.63)
P = 0.58
CI, confidence interval; HCVA, high-contrast visual acuity; LCLA, low-contrast letter acuity; PP, per-protocol; RGCL/IPL, retinal ganglion cell layer/
inner plexiform layer; RNFL, retinal nerve fiber layer; SD-OCT, spectral-domain optical coherence tomography; VEP, visual evoked potential.
1Adjusted mean versus baseline of the fellow eye.
2Adjusted mean versus baseline of the affected eye.
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demyelination and subsequent remyelination in models
of optic neuritis.15,16 RENEW used the latency of the
unaffected eye at baseline to measure the extent of
recovery in the affected eye across 32 weeks. Due to the
likely influence of baseline demographic and disease
severity on the potential efficacy of opicinumab in AON,
the study explored efficacy across prespecified demo-
graphic and baseline disease characteristics: age range
18–55 years, disease duration between 1 and 28 days,
time to steroid administration, and variable baseline dis-
ease severity (mild–severe).11
Of all the parameters analyzed, only age had a statisti-
cally significant treatment effect with a strong trend in
the subgroup-by-treatment interaction analysis. We
expected trends rather than significant P values due to
the small sample size of the RENEW study. In fact, the
primary endpoint of RENEW was not itself powered for
statistical significance.11 Among all subgroups analyzed,
the greatest VEP latency recovery was observed in the
older half of participants treated with opicinumab in the
PP population (baseline age ≥33 years), while the worst
latency delay was observed in the older participants trea-
ted with placebo. The younger half (<33 years of age)
experienced similar and intermediate degrees of recovery
in the two treatment arms.
The finding that older placebo-treated participants
experienced worse VEP latency recovery is consistent with
the biological concept that spontaneous remyelination is
negatively affected by aging.17–21 That the strongest opici-
numab treatment effect was observed in this subgroup,
suggests that LINGO-1 blockade may be more effective in
individuals whose initial clinical episode of CNS demyeli-
nation occurs at an older age. Results from a Phase 2 trial
showing a modest reduction in VEP latency in patients
(mean age = 40.1 years) with relapsing MS with preexist-
ing optic neuritis and good preservation of the RNFL
treated with clemastine fumarate are consistent with
this finding.22
The hypothesis that older individuals with AON may
be more responsive to LINGO-1 blockade with opicinu-
mab could be explained by one or more of the following
reasons. First, younger participants may have greater
inherent recovery potential and spontaneous remyelina-
tion, which may dampen any therapeutic effect of opici-
numab; conversely, intrinsic remyelination may be weaker
in older participants, with a greater margin for therapeu-
tic enhancement in this subgroup.21 Second, younger par-
ticipants may be less responsive to opicinumab because
increased LINGO-1 expression may not play a role in the
lack of spontaneous remyelination. Third, younger partic-
ipants are more likely to have active disease activity (even
asymptomatic MS) compared with older patients, con-
founding any beneficial treatment effect of reparative
candidate treatments such as opicinumab. Fourth, the ini-
tial demyelination may be more severe in the older partic-
ipants making it unlikely for spontaneous remyelination
to be clinically meaningful. In this context, conduction
block at baseline was more frequent in older participants
(8/35 vs. 3/34 for younger participants). Fifth, the find-
ings may be spurious, possibly attributable to chance.
Additional efficacy studies with opicinumab are needed to
shed light on the effect of baseline age on response to
therapeutic remyelination.
The lack of statistically significant interaction between
the primary endpoint and treatment window or timing of
steroid administration at week 24 may be attributed to
the small sample size, as the RENEW study was powered
only for an 80% treatment effect with one-tail alpha of
0.1 for the primary endpoint. Notwithstanding, there
appears to be a consistent numerical trend suggesting
greater improvement in patients treated sooner (<25 days
from onset of AON) with opicinumab (P = 0.12, vs. pla-
cebo) and in patients randomized to opicinumab and
treated sooner with high-dose methylprednisolone
(<15 days from onset of AON; P = 0.14, vs. placebo).
The axonal protective potential of opicinumab, if given
soon after onset of CNS inflammatory demyelinating
injury, should be evaluated in additional studies aiming
to initiate treatment sooner that the 28-day window in
this study. Results from a single-center academic study
with phenytoin that enrolled within 14 days of AON
onset suggest that treatment with candidate RGCL protec-
tive agents could be initiated earlier after onset of
AON symptoms.23
The apparent lack of influence of visual impairment
and brain MRI data in stratifying patients according to
VEP latency prolongation at week 24 is noteworthy. How-
ever, the subgroup analyses showed a trend for a treat-
ment benefit in participants with more impaired
pretreatment HCVA (P = 0.08). This could indicate that
opicinumab-mediated repair via remyelination may be
more effective and relevant in participants with greater
pre-treatment HCVA impairment, barring severe injury to
the optic nerve including the ganglion cell neurons in the
retina. In this study, the interaction between VEP latency
and brain T2 lesion volume is difficult to interpret due to
the small sample size and the focus on patients with first
episode of AON.
Based on data from the post hoc analyses comparing
measures of structure and function, improvement on the
primary endpoint was associated with less reduction in
RGCL/IPL and RNFL thickness (P = 0.02 and P = 0.08,
respectively), which occurred early on. Corresponding
findings in the ITT population were also statistically sig-
nificant for both (Table S2). Our data suggest that an
adjusted mean loss in RGCL/IPL of approximately 4–
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5 lm (Table 3) may be used as a predictor of poor VEP
latency recovery following AON. This is of similar magni-
tude to the average loss on RNFL thickness in MS as a
result of AON.24
The initial safety analyses highlighted that the group
randomized to opicinumab appeared to have a higher fre-
quency of weight gain than the placebo group.11 Weight
gain is unlikely to have been related to intravenous steroid
pretreatment because of short-term single use (3–5 days),
although individual differential effects of steroids are pos-
sible. It is unclear if the weight gain may be related to
more severe disease because neither restricted mobility nor
decreased physical activity was assessed. There does not
appear to be evidence in the literature that acute visual
impairment is associated with weight gain. In addition, no
evidence of weight gain was seen in previous preclinical
studies of opicinumab in toxicology studies (Biogen, data
on file) or in clinical (Phase I) studies in healthy volun-
teers or individuals with MS.8 Analysis of results from
SYNERGY, which assessed opicinumab in disabled partici-
pants with relapsing-remitting and secondary progressive
MS treated for ≤18 months, may further elucidate whether
weight gain may be treatment-related.25
The main limitation of these RENEW subgroup analy-
ses is the small sample size. RENEW was designed to
assess efficacy trends early in clinical development of opi-
cinumab on both the primary endpoint and subgroup
analysis. This likely explains why none of the prespecified
baseline characteristics included in the subgroup-by-treat-
ment interaction analyses reached statistical significance.
Although the majority of the subgroup analyses were pre-
specified in the statistical analysis plan, the observations
require further investigation. A systematic analysis of all
baseline characteristics was not performed due to the
small sample size. All reported results are based on a uni-
variate subgroup analysis approach of prespecified base-
line characteristics that may not account for all
confounding issues; data mining results and conclusions
from such analyses may need further study with larger
sample size for validation.
These RENEW subgroup analyses could have important
implications for the design of future clinical trials of CNS
remyelinating therapies in the context of AON and
beyond. Importantly, these analyses support further inves-
tigation of opicinumab as a potential treatment for MS
and other CNS demyelinating diseases. Future subgroup
analyses in a larger population, including participants
enrolled in the recently completed SYNERGY trial25 and
the ongoing AFFINITY study (NCT03222973) will help to
confirm whether age and other baseline demographic or
disease characteristics can identify subgroups of patients
more likely to benefit from therapeutic remyelination
with opicinumab.
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Appendix S1. RENEW study investigators.
Figure S1. Retinal ganglion cell layer/inner plexiform
layer (RGCL/IPL) thinning (spectral-domain optical
coherence tomography) at weeks 4 and 24 in participants
from the intent-to-treat population with and without
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dence interval.
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